DDInter1168 DDInter1960
Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.
Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds.[A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be synthesized without loss of proper bond formation or structural elements.[A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.[A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt. To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.
Methdilazine {u} (Compound) resembles {v} (Compound) Thioproperazine
Methdilazine {u} (Compound) resembles {v} (Compound) Epinastine
Methdilazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyproheptadine
Methdilazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Methdilazine {u} (Compound) binds {v} (Gene) HRH1
Methdilazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Methdilazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Methdilazine {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Methdilazine {u} may lead to a major life threatening interaction when taken with {v} Deutetrabenazine
Methdilazine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perphenazine
Methdilazine (Compound) resembles Thioproperazine (Compound)
Methdilazine (Compound) resembles Epinastine (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Methdilazine (Compound) binds HRH1 (Gene)
Methdilazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Methdilazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Methdilazine may lead to a major life threatening interaction when taken with Dextropropoxyphene
Methdilazine may lead to a major life threatening interaction when taken with Deutetrabenazine
Methdilazine (Compound) resembles Perphenazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine